Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.795 USD | -0.63% | -13.51% | -1.99% |
04-25 | Transcript : HOOKIPA Pharma Inc. - Special Call | |
04-25 | HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.99% | 79.16M | |
+32.77% | 698B | |
+26.51% | 568B | |
-4.55% | 358B | |
+19.54% | 328B | |
+3.51% | 283B | |
+16.34% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+9.11% | 165B |
- Stock Market
- Equities
- HOOK Stock
- News HOOKIPA Pharma Inc.
- RBC Cuts Price Target on HOOKIPA Pharma to $9 From $11, Maintains Outperform Rating, Speculative Risk Qualifier